Effectiveness and safety of orally administered immunotherapy for food allergies: a systematic review and meta-analysis by Nurmatov, Ulugbek et al.
Systematic review with meta-analysis
Effectiveness and safety of orally administered immunotherapy
for food allergies: a systematic review and meta-analysis
Ulugbek Nurmatov1, Graham Devereux2, Allison Worth1, Laura Healy1 and Aziz Sheikh1*
1Allergy and Respiratory Research Group, Centre for Population Health Sciences, The University of Edinburgh,
Medical School, Doorway 3, Teviot Place, Edinburgh EH8 9AG, UK
2Department of Child Health, Royal Aberdeen Children’s Hospital, University of Aberdeen, Aberdeen AB25 2ZP, UK
(Submitted 3 January 2013 – Final revision received 15 May 2013 – Accepted 19 June 2013 – First published online 15 August 2013)
Abstract
The aim of using oral and sublingual immunotherapy with food allergies is to enable the safe consumption of foods containing these aller-
gens in patients with food allergies. In the present study, a systematic review of intervention studies was undertaken; this involved the
searching of eleven international databases for controlled clinical trials. We identified 1152 potentially relevant papers, from which we
selected twenty-two reports of twenty-one eligible trials (i.e. eighteen randomised controlled trials and three controlled clinical trials).
The meta-analysis revealed a substantially lower risk of reactions to the relevant food allergen in those receiving orally administered immu-
notherapy (risk ratios (RR) 0·21, 95 % CI 0·12, 0·38). The meta-analysis of immunological data demonstrated that skin prick test responses to
the relevant food allergen significantly decreased with immunotherapy (mean difference 22·96 mm, 95 % CI 24·48, 21·45), while aller-
gen-specific IgG4 levels increased by an average of 19·9 (95 % CI 17·1, 22·6)mg/ml. Sensitivity analyses excluding studies at the highest risk
of bias and subgroup analyses in relation to specific food allergens and treatment approaches generated comparable summary estimates of
effectiveness and immunological changes. Pooling of the safety data revealed an increased risk of local (i.e. minor oropharyngeal/gastro-
intestinal) adverse reactions with immunotherapy (RR 1·47, 95 % CI 1·11, 1·95); there was a non-significant increased average risk of
systemic adverse reactions with immunotherapy (RR 1·08, 95 % CI 0·97, 1·19). There is strong evidence that orally administered immu-
notherapy can induce immunomodulatory changes and thereby promote desensitisation to a range of foods. However, given the paucity
of evidence on longer-term safety, effectiveness and cost-effectiveness, orally administered immunotherapy should not be used outside
experimental conditions presently.
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Food allergies are responsible for the considerable rise in
morbidity and, in some cases, mortality. There are concerns
that the incidence, prevalence and severity of food allergies
are increasing in many parts of the world, particularly in
children(1–3). Food allergies are associated with significant
reductions in the quality of life of both the affected individuals
and their family members, which lead to a combination of the
restrictive lifestyle associated with living with food allergy, the
often considerable difficulties in avoiding the responsible food
allergens and the potential for the occurrence of sudden life-
threatening anaphylactic reactions(4,5).
Until now, the cornerstones of the clinical management of
food allergies have been the identification and complete
avoidance of the responsible food allergen(s)(6,7) and, in
those who have had severe reactions, the carriage and use
of self-injectable epinephrine (adrenaline). This management
strategy is challenging, requiring considerable vigilance to
avoid accidental exposure(8,9). In contrast to meticulous aller-
gen avoidance, immunotherapy is the deliberate controlled
exposure of patients with food allergy to extremely low, but
progressively increasing doses of the offending allergen over
a period of weeks or months(10). The aim is to reduce
immunological sensitivity to the allergen such that patients
can safely consume food containing the allergen or, at the
very least, not react to an accidental low-dose exposure.
This approach has, for example, over the last century
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become an established clinical practice in relation to the
treatment of severe pollen, insect venom and drug allergies.
Although the first case report of successful immunotherapy
to food allergies was reported over a 100 years ago(11),
this treatment is yet to become established in the manage-
ment of people with food allergy. The increasing numbers
of people living with potentially life-threatening food
allergies and the preventable loss of life from food-
triggered anaphylaxis have stimulated renewed interest in
the role of orally administered immunotherapy – i.e. via
the oral and sublingual routes – in the management of
people with food allergy. This is particularly true for
patients/parents of affected children who have been hear-
tened by the widespread media coverage of a ‘cure’ for
food allergies, but who also often express frustration that
this has not been translated into clinical practice yet.
In order to inform ongoing scientific and clinical deliberations
on the role of orally administered immunotherapy, in the
present study, we sought to critically assess the evidence on
the effectiveness, mechanisms and safety of this potentially
disease-modifying treatment approach(12–20).
Methods
Literature search and study selection
We searched for randomised controlled trials, quasi-
randomised controlled trials and controlled clinical trials
investigating the role of oral immunotherapy (OIT) and sub-
lingual immunotherapy (SLIT) in children and adults with
IgE-mediated (i.e. immediate hypersensitivity) food allergy.
Our primary outcomes of interest were recovery rate
from food allergy as assessed by the ability to consume the
offending food allergen while receiving treatment (i.e. desen-
sitisation) and, in particular, success rates for the ability
to consume the food safely after completion of treatment
(i.e. tolerance). Secondary outcomes of interest were immuno-
logical changes; the frequency and degree of local (i.e. minor
oropharyngeal/gastrointestinal) and systematic (i.e. urticaria,
angio-oedema, asthma and anaphylaxis) adverse events
during treatment; quality of life; health service utilisation
including emergency hospital admissions and emergency
treatments; and data on costs from the perspective of health
services.
For this purpose, we searched eleven international
databases for published material: Cochrane Library; MEDLINE;
EMBASE; LILACS; ISI Web of Science; BIOSIS; Global
Health; AMED; TRIP; CAB; CINAHL (for search terms
used, see Appendix 1, available online). In addition, we
searched Internet-based international trial repositories such
as www.clinicaltrials.gov and www.controlled-trials.com and
contacted international experts in order to locate unpublished
and ongoing work (see Appendix 2, available online).
Our database searches covered the period from January
1990 to March 2013. The bibliographies of all eligible
studies were scrutinised to identify additional possible studies.
No language restrictions were imposed, and where necessary,
manuscripts were translated into English.
Data abstraction
The titles and abstracts of the identified studies were checked
and independently reviewed by two researchers (U. N. and
G. D.). The full text of all the potentially eligible studies
was assessed for eligibility against the eligibility criteria.
Data were independently abstracted by two reviewers onto
a customised data extraction sheet. Any disagreements were
resolved through discussion, with A. S. arbitrating if an agree-
ment could not be reached.
Quality assessment
The methodological quality of the included randomised
controlled trials and quasi-randomised controlled trials was
independently assessed using the methods detailed in section
eight of the Cochrane Handbook for Systematic Reviews of
Interventions (21). Critical appraisal of the controlled clinical
trials was undertaken using the Cochrane Effective Practice
and Organisation of Care (EPOC) guidelines(22). We concen-
trated on using the following six parameters to assess
quality: adequate sequence generation; allocation conceal-
ment; blinding/patient-related outcomes; the addressing of
incomplete outcome data; the absence of selective reporting
and the absence of other sources of bias. Each parameter of
trial quality was graded: A – low risk of bias; B – moderate
risk of bias; C – high risk of bias, and an overall assessment
of quality for each trial using these three categories was car-
ried out through consensus discussion among the reviewers.
Data synthesis
The clinical and statistical appropriateness of meta-analyses
was considered for all outcomes of interest. Because of the
clinical heterogeneity of the populations and interventions
studied, we carried out a meta-analysis using random-effects
modelling using Review Manager 5.1(21,23). We calculated
mean differences as continuous outcomes and risk ratios (RR)
with 95 % CI. Because of a lack of consistency in the reporting
of immunological outcomes (e.g. skin prick test, IgE and IgG4),
original data were obtained from the authors of several trials.
A priori sensitivity analyses were undertaken by study design
and quality to assess the robustness of findings and explain
any heterogeneity uncovered; where possible, subgroup
analyses were undertaken on the basis of OIT and SLIT and
the allergy being treated for. We graphically assessed for the
possibility of publication bias using funnel plots.
Results
Our searches identified 1152 potentially relevant papers, from
which we identified twenty-one trials (reported in twenty-two
papers) that satisfied our inclusion criteria (Fig. 1). There were
eighteen randomised controlled trials(14,18,24–38) and three con-
trolled clinical trials(15,39,40) (Table 1). Of these trials, seventeen
had investigated OIT(14,15,18,24,25,30–40) and four had investigated
SLIT(26–29). There was one report that included two independent
randomised controlled trials on cows’ milk and hens’ eggs(34).
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Apart from these, twelve studies had focused on cows’
milk(14,15,18,25,31,32,34,37,39,40), eight on hens’ eggs(14,15,24,30,33,34,36,40),
four on peanut(28,29,38,40) and five other studies on a variety of
food allergens including hazelnut(26), peach(27), orange(40),
apple(15,36,40), ‘corn’(40), fish(15,36,40), bean(15,40), wheat(15) and
lettuce(40) (see Appendix 3, available online). There were two
follow-up studies(41,42), and these focused on SLIT for hazelnut(26)
and peach allergies(27). Translation was required for two
papers(39,43). Among the trials, sixteen had conducted studies on
only children(14,15,24,25,29–39), two on only adults(26,27) and three on
both children and adults(18,28,40).
Quality assessment
Quality assessment of these studies revealed that three of the
randomised controlled trials were at a low risk of bias(28,31,38),
a further five randomised controlled trials(18,24,27,29,32) were
judged to be at a moderate risk of bias and the remaining ten
randomised controlled trials and the three controlled clinical
trials(14,15,25,26,30,33–37,39,40) were all judged to be at a high risk
of bias (see Appendix 4 for further details, available online).
Impact on primary outcomes
Desensitisation. The effectiveness of immunotherapy was
compared with that of placebo with food avoidance/strict
elimination diet(18,24–29,31,37,38) or food avoidance/strict elim-
ination diet alone(14,15,30,32–34,36,39,40). In two studies(35,37)
that had investigated the effectiveness of OIT for cows’ milk
allergy, soya milk was used as the control. A meta-analysis
of the risk of persisting food allergy at the completion of
the intervention period as assessed by a double-blind
721 potentially relevant papers from eleven databases
identified
After de-duplication 626 potentially relevant papers
included for screening
606 papers excluded for not
meeting review criteria
Twenty potentially appropriate
abstracts reviewed
TRIP
12
MEDLINE
125
EMBASE
253
Global Health
30
AMED
1
Web of Science
125
CAB
30
BIOSIS
121
Cochrane Library
8
CINAHL
14
LILACS
2
Four papers defined as
uncontrolled studies
Ninety-five
duplications excluded 
Twenty-two papers from twenty-one
studies included in this review
(eighteen RCT  and three CCT)
OIT 17
SLIT 4 
Cows’ milk 12  
Peanuts 4 
Hens’ eggs 8 
Other 5  
Updated search
(2012–2013)
revealed six new
RCT
Fig. 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram. RCT, randomised controlled trial; CCT, controlled clinical
trial; OIT, oral immunotherapy; SLIT, sublingual immunotherapy. (A colour version of this figure can be found online at http://www.journals.cambridge.org/bjn)
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Table 1. Description of the included studies (n 21)
Foods
Type of
immu-
notherapy Evidence of allergy Clinical outcomes HSU Immunological outcomes
First author, year and
country
Cows’
milk
Hens’
eggs Peanut Hazelnut Peach Apple Fish Other* OIT SLIT SPT SBPCFC DBPCFC Desensitisation Tolerance QOL LR SR
Unscheduled
visits
Cost-
effectiveness
Total
IgE
Sp
IgE IgG IgG4 Other†
RCT
Burks (2012)(24), USA U U U U U U U U
Caminiti (2009)(25),
Italy
U U U U U U U
Enrique (2005)(26),
Spain
Enrique (2008)(41)‡
U U U U U U U U U U
Fernandez-Rivas
(2009)(27), Spain
Garcia (2010)(42)‡
U U U U U U U U U
Fleischer (2013)(28),
USA
U U U U U U U U U U
Kim (2011)(29), USA U U U U U U U U U U
Lacono (2013)(30), Italy U U U U U U U U
Longo (2008)(31), Italy U U U U U U U U U
Martorell (2011)(32),
Spain
U U U U U U U U
Meglio (2013)(33), Italy U U U U U U U U U U
Morisset (2007)(34)§,
France
U U U U U U U U
Morisset (2007)(34)k,
France
U U U U U U U U
Pajno (2010)(35), Italy U U U U U U U U U
Patriarca (1998)(36),
Italy
U U U U U U U U U U U
Salmivesi (2012)(37),
Finland
U U U U U U U
Skripak (2008)(18),
USA
U U U U U U U U U U U
Staden (2007)(14),
Germany
U U U U U U U U U
Varshney (2011)(38),
USA
U U U U U U U U U U U
CCT
Mansouri (2007)(39),
Iran
U U U U U U U U U
Patriarca (2003)(40),
Italy
U U U U U U U U U U U U U U U
Patriarca (2007)(15),
Italy
U U U U U U U U U U U U U U U
HSU, health service utilisation; OIT, oral immunotherapy; SLIT, sublingual immunotherapy; SPT, skin prick test; SBPCFC, single-blind placebo-controlled food challenge; DBPCFC, double-blind placebo-controlled food challenge;
QOL, quality of life; LR, local reactions; SR, systemic reactions; Sp IgE, specific IgE, RCT, randomised controlled trial; CCT, controlled clinical trial.
* Other includes orange, maize, bean and lettuce.
† Other includes IL-4, IL-5, IL-10, IL-13, tumour growth factor b, interferon-g, basophil activation and T regulatory cells.
‡ Follow-up study.
§ Cows’ milk RCT.
kHens’ egg RCT.
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Study or subgroup
Study or subgroup
Burks 2012(24)
(a)
(b)
(c)
Caminiti 2009(25)
Fernandez-Rivas 2009(27)
Fleischer 2013(28)
Kim 2011(29)
Lacono 2013(30)
Longo 2008(31)
Mansouri 2007(39)
Martorell 2011(32)
Meglio 2013(33)
Morisset 2007(34)
Morisset 2007(34)
Pajno 2010(35)
Patriarca 1998(36)
Patriarca 2003(40)
Patriarca 2007(15)
Skripak 2008(18)
Staden 2007(14)
Varshney 2011(38)
Total (95% CI)
Total (95% CI)
Total events
Total events
Burks 2012(24)
Fernandez-Rivas 2009(27)
Fleischer 2013(28)
Kim 2011(29)
Longo 2008(31)
Martorell 2011(32)
Varshney 2011(38)
Skripak 2008(18)
Heterogeneity: t2 = 0·82; c2 = 76·77, df = 19 (P < 0·00001) ; I 2 = 75 %
Test for overall effect: Z = 5·33 (P < 0·00001)
Heterogeneity: t2 = 0·56; c2 = 54·42, df = 16 (P < 0·00001) ; I 2 = 71 %
Test for overall effect: Z  = 4·79 (P < 0·00001)
Enrique 2005(26)
Burks 2012(24)
Caminiti 2009(25)
Fernandez-Rivas 2009(27)
Fleischer 2013(28)
Kim 2011(29)
Lacono 2013(30)
Longo 2008(31)
Martorell 2011(32)
Meglio 2013(33)
Morisset 2007(34)
Morisset 2007(34)
Pajno 2010(35)
Patriarca 1998(36)
Skripak 2008(18)
Staden 2007(14)
Varshney 2011(38)
Enrique 2005(26)
Control
327
61 334
484 100·0
0·005
Favours experimental Favours control
0·1 1 10 200
Total (95% CI)
Total events
Heterogeneity: t2 = 0·45; c2 = 13·33, df = 7 (P = 0·06) ; I 2 = 47 %
Test for overall effect: Z = 4·21 (P < 0·0001)
0·005
Favours experimental Favours control
0·1 1 10 200
0·005
Favours experimental Favours control
0·1 1 10 200
0·21 0·12, 0·38
Events Total
0 15 22 40 3·0 0·00, 0·88
0·01, 2·98
0·03, 1·59
0·29, 1·64
0·07, 0·63
0·00, 0·96
0·00, 0·80
0·00, 0·71
0·00, 0·62
0·13, 0·50
0·07, 0·90
0·47, 0·92
0·47, 1·02
0·00, 0·75
0·00, 0·83
0·00, 0·60
0·00, 0·80
0·00, 1·03
0·43, 2·15
0·00, 0·91
3·1
4·5
8·2
7·4
3·1
3·0
2·9
3·0
8·9
6·7
9·8
9·7
3·0
3·0
3·0
3·0
3·1
3·1
8·4
0·06
0·20
0·22
0·70
0·21
0·07
0·05
0·04
0·04
0·26
0·25
0·66
0·69
0·05
0·05
0·04
0·05
0·07
0·06
0·96
0·00, 0·88
0·01, 2·98
0·03, 1·59
0·29, 1·64
0·07, 0·63
0·00, 0·96
0·00, 0·80
0·00, 0·71
0·13, 0·50
0·07, 0·90
0·47, 0·92
0·47, 1·02
0·00, 0·75
0·00, 0·83
0·00, 1·03
0·43, 2·15
0·00, 0·91
0·00, 0·91
0·00, 1·03
0·13, 0·50
0·00, 0·71
0·00, 0·96
0·07, 0·63
0·29, 1·64
0·00, 0·88
0·06
0·20
0·22
0·70
0·21
0·07
0·05
0·04
0·26
0·25
0·66
0·69
0·05
0·05
0·07
0·06
0·96
3
12
37
20
11
10
30
20
30
10
28
51
15
14
59
36
13
26
19
2
5
14
14
11
9
11
18
27
8
24
34
10
12
45
31
12
9
16
3
11
19
20
7
10
30
13
30
10
32
39
15
10
16
10
7
21
9
0
1
5
3
0
0
0
0
7
2
18
18
0
0
0
0
0
0
7
Events Total
Weight
(%) RR 95% CI
Experimental
0 15 22 40 2·8
2·9
4·5
9·5
8·3
2·9
2·9
2·8
10·6
7·3
12·1
11·9
2·8
2·9
2·9
9·8
2·9
3
12
37
20
11
10
30
30
10
28
51
15
14
13
26
19
2
5
14
14
11
9
11
27
8
24
34
10
12
12
9
16
3
11
19
20
7
10
10
30
30
32
39
15
10
7
21
9
288 369 100·0% 0·28 0·16, 0·47
137
12715
200 100·0 0·20 0·09, 0·42
0
1
5
3
0
0
0
7
2
18
18
0
0
0
7
0
61 240
6·3
6·3
26·2
6·0
6·4
19·6
23·0
6·2
19
13
30
30
11
20
37
40
0·06
0·07
0·26
0·04
0·07
0·21
0·70
0·06
16
12
27
11
11
14
14
22
9
7
30
30
7
20
19
15
0
0
0
0
3
5
0
7
Study or subgroup
Control
Events Total Events Total
Weight
(%)
Experimental
Control
Events Total Events Total
Weight
(%) RR
RR
95% CI
95% CI
Experimental
RR
M-H, Random, 95 % CI
RR
M-H, Random, 95 % CI
RR
M-H, Random, 95 % CI
Fig. 2. (a) Risk ratios (RR) of persisting food allergy as assessed by double-blind placebo-controlled food challenge in oral immunotherapy (OIT) or sublingual
immunotherapy (SLIT) v. controls, (b) sensitivity analysis RR of food allergy after OIT or SLIT (only randomised controlled trial) and (c) sensitivity analysis RR of
food allergy after OIT or SLIT (only grade A and B studies). (A colour version of this figure can be found online at http://www.journals.cambridge.org/bjn)
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placebo-controlled food challenge was possible based on
data obtained from all the twenty trials, which revealed a
substantially reduced average risk of persisting food allergy
in treated patients (RR 0·21, 95 % CI 0·12, 0·38; Fig. 2(a))
(14,15,18,24–36,38–40). A sensitivity analysis omitting the studies
that had utilised a clinical diagnosis of food allergy (well-
documented reaction within 60 min of consuming food and
elevated specific IgE levels and/or a positive skin prick test)
as an inclusion criterion instead of a confirmatory double-
blind placebo-controlled food challenge made little difference
to the summary estimates (RR 0·26, 95 % CI 0·15, 0·45) (see
Appendix 5, Supplementary Fig. S1, available online)
Sensitivity analysis of the seventeen randomised controlled
trials found a comparable average risk reduction (RR 0·28,
95 % CI 0·16, 0·47; Fig. 2(b)). Further sensitivity analysis
excluding all the trials judged to be at a high risk of bias
also demonstrated a substantial average risk reduction (RR
0·20, 95 % CI 0·09, 0·42)(18,24,27–29,31,32,38) (Fig. 2(c)).
Subgroup analyses revealed that both oral (RR 0·19, 95 % CI
0·09, 0·37) and sublingual approaches had comparable
effectiveness (RR 0·30, 95 % CI 0·12, 0·78) (Figs. 3 and 4,
respectively).
Furthermore, we were able to carry out subgroup analyses
for eight trials that had investigated immunotherapy for
cows’ milk allergy, four trials on hens’ egg allergy and three
trials on peanut allergy. These analyses demonstrated that
OIT approaches substantially reduced the risk of cows’ milk
(RR 0·14, 95 % CI 0·04, 0·44)(18,25,31,32,34–36,39), hens’ egg
(RR 0·19, 95 % CI 0·04, 0·99)(24,30,33,34) and peanut (RR 0·16,
95 % CI 0·06, 0·41)(28,29,38) allergies (see Appendix 5,
Supplementary Figs. S2, S3 and S4, available online).
There was no clear evidence of publication bias (Fig. 5).
Tolerance. Long-term tolerance was investigated by two
studies, with it being studied after OIT in children with allergy
to cows’ milk and hens’ eggs(14,24). After completion of the
desensitisation and maintenance phases, the subjects were
subjected to a 1- to 2-month strict elimination (washout)
Study or subgroup
Control
Events Total Events
22 40 4·1
4·2
4·2
4·1
4·2
11·1
8·6
12·0
11·9
4·1
4·2
4·2
4·2
4·2
10·6
4·2 0·06
0·96
0·07
0·05
0·04
0·05
0·05
0·69
0·66
0·25
0·26
0·04
0·04
0·05
0·20
0·06 0·00, 0·88
0·01, 2·98
0·00, 0·80
0·00, 0·71
0·00, 0·62
0·13, 0·50
0·07, 0·90
0·47, 0·92
0·47, 1·02
0·00, 0·75
0·00, 0·83
0·00, 0·60
0·00, 0·80
0·00, 1·03
0·43, 2·15
0·00, 0·91
3
10
30
20
30
10
28
51
15
14
59
36
13
26
19
2
9
11
18
27
8
24
34
10
12
45
31
12
9
169
21
7
10
16
10
15
39
32
10
30
13
30
10
3
150
0
0
0
0
7
2
18
18
0
0
0
0
0
7
0
Total
Weight
(%) 95 % CIRR
Experimental
Burks 2012(24)
Caminiti 2009(25)
Lacono 2013(30)
Longo 2008(31)
Mansouri 2007(39)
Martorell 2011(32)
Meglio 2013(33)
Morisset 2007(34)
Morisset 2007(34)
Pajno 2010(35)
Patriarca 1998(36)
Patriarca 2003(40)
Patriarca 2007(15)
Skripak 2008(18)
Staden 2007(14)
Varshney 2011(38)
Total (95 % CI)
Total events 52 290
Heterogeneity: t2 = 0·99; c2 = 72·51, df = 15 (P < 0·00001); I 2 = 79 %
Test for overall effect: Z = 4·80 (P < 0·00001)
270 404 100·0 0·19 0·09, 0·37
0·005 0·1 1 10 200
Favours experimental Favours control
RR
M-H, Random, 95 % CI
Fig. 3. Risk ratios (RR) of persisting food allergy as assessed by double-blind placebo-controlled food challenge in oral immunotherapy v. controls. (A colour
version of this figure can be found online at http://www.journals.cambridge.org/bjn)
Study or subgroup
Control
Events
1
5
3
0 7
57
9 44
80 100·0 0·30 0·12, 0·78
0·005 0·1 1 10 200
Favours experimental Favours control
20
19
11
11
14
14
5
11
20
37
12
10·3
33·4
39·9
16·4
0·07
0·21
0·70
0·22
0·00, 0·96
0·07, 0·63
0·29, 1·64
0·03, 1·59
Total Events Total
Weight
(%) RR 95 % CI
Experimental
Enrique 2005(26)
Fernandez-Rivas 2009(27)
Fleischer 2013(28)
Kim 2011(29)
Total (95 % CI)
Total events
Heterogeneity: t2 = 0·39; c2 = 5·39, df = 3 (P = 0·15); I 2 = 44 %
Test for overall effect: Z = 2·46 (P = 0·01)
RR
M-H, Random, 95 % CI
Fig. 4. Risk ratios (RR) of persisting food allergy as assessed by double-blind placebo-controlled food challenge in sublingual immunotherapy v. controls. (A colour
version of this figure can be found online at http://www.journals.cambridge.org/bjn)
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period before the follow-up double-blind placebo-controlled
food challenge. Burks et al.(24) reported that of the forty chil-
dren undergoing hens’ egg OIT, eleven (28 %) were con-
sidered to have sustained unresponsiveness after cessation
of OIT (i.e. tolerance). Staden et al.(14) reported that there
was no difference in the development of long-term tolerance
between OIT and control subjects (35 v. 36 %), suggesting that
regular allergen exposure was required to maintain the state of
desensitisation.
Impact on secondary outcomes
Immunological outcomes. Many of the trials included data
on the effects of OIT or SLIT on immunological outcomes
(Appendices 6 and 7, available online). Skin prick test responses
to the responsible food allergen before and after immunother-
apy were measured by fifteen studies(14,15,18,24,27–30,32–34,38–40),
food allergen-specific IgE levels by eighteen studies
(14,15,18,24,26–32,34–36,38–40) and food allergen-specific IgG4
levels by eleven studies(15,18,24,26–29,33,35,38,40).
Allergen skin prick tests. The results of allergen skin prick
tests were expressed in differing formats. However, we were
able to conduct a meta-analysis of skin prick test data obtained
from five studies using a combination of published data and
original data supplied by the investigators. OIT/SLIT reduced
the magnitude of the mean wheal diameter response to the
responsible food allergen by 22·96 (95 % CI 24·48,
21·45) mm (Fig. 6), and of the ten studies that had failed to pro-
vide us with original data(14,15,31,34,36), eight(14,15,24,26,30–32,35)
reported that OIT/SLIT reduced skin prick test reactivity, with
three studies reporting no change(28,33,35). Subgroup analysis
of data showed that OIT for cows’ milk allergy also reduced
the magnitude of the mean wheal diameter response to cows’
milk by 23·42 (95 % CI 26·18, 20·66) mm (see Appendix 5,
Supplementary Fig. S5, available online).
Food allergen-specific IgE tests. The results of food aller-
gen-specific IgE tests were expressed in differing formats,
but we were able to conduct a meta-analysis of food allergen-
specific IgE data obtained from six studies using published
data and original data supplied by the investigators.
Completion of OIT/SLIT did not significantly reduce the
allergen-specific IgE levels (25·2 (95 % CI 212·3, 1·99) kU/l;
Fig. 7). Of the studies that had failed to provide us with
original data and not included in the meta-analysis,
four(24,27,28,35) reported that orally administered immunother-
apy did not change the allergen-specific IgE levels and
seven(14,15,29,30,32,33,40) reported that OIT/SLIT reduced their
levels. Subgroup analysis of data showed that OIT also did
not significantly reduce these levels (28·96 for cows’ milk
allergy, 95 % CI 228·64, 10·73; see Appendix 5, Supplemen-
tary Fig. S6, available online).
Food allergen-specific IgG4 tests. The results of food
allergen-specific IgG4 tests were expressed in differing
formats, but we were able to conduct a meta-analysis of
allergen-specific IgG4 data obtained from three studies using
published data and original data supplied by the investigators.
OIT/SLIT increased the allergen-specific IgG4 levels by 19·9
(95 % CI 17·1, 22·6)mg/ml (Fig. 8), and five of the seven
studies that had failed to provide us with original data and
not included in the meta-analysis also reported increases in
their levels(15,24,27,29,40) and two studies(28,33) reported no
changes. Subgroup analysis of food allergen-specific IgG4
levels during OIT for cows’ milk allergy also showed an
increase in their levels (19·8 (95 % CI 14·32, 25·34)mg/ml;
see Appendix 5, Supplementary Fig. S7, available online).
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Fig. 5. Funnel plot showing: risk ratios (RR) of persistent food allergy after oral
or sublingual immunotherapy. (A colour version of this figure can be found
online at http://www.journals.cambridge.org/bjn)
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Fig. 6. Skin prick test (wheal in mm) following oral immunotherapy for food allergy. (A colour version of this figure can be found online at http://www.journals.
cambridge.org/bjn)
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Safety
Systemic reactions. Data on the occurrence of systemic
(i.e. urticaria, asthma and anaphylaxis) adverse reactions
were available from five trials. Meta-analysis of safety data
obtained from these trials indicated a modest increased risk
of systemic adverse reactions associated with treatment,
but this was imprecisely estimated (RR 1·08, 95 % CI 0·97,
1·19)(26,27,35,36,38,39) (Fig. 9). Some studies reported no
‘severe’ side effects(24,30,32,33). Focusing on only higher-quality
studies (i.e. gradeAandBstudies) ina sensitivity analysisproduced
comparable summary estimates of the risk of adverse events (RR
1·02, 95% CI 0·89, 1·17) (see Appendix 5, Supplementary Fig. S8,
available online)(27,38). However, subgroup analysis of safety data
obtained from OIT studies(35,36,39) for cows’ milk allergy more
clearly demonstrated these increased risks (RR 1·23, 95% CI 1·03,
1·48; see Appendix 5, Supplementary Fig. S9, available online).
Local reactions. Data on the occurrence of local (minor oro-
pharyngeal/gastrointestinal) adverse reactions were available
from nine studies; these revealed an increased risk associated
with OIT/SLIT (RR 1·47, 95 % CI 1·11, 1·95) (Fig. 10). Studies
not included in the meta-analysis reported the incidence of
local reactions in relation to doses administered, indicating
that OIT was associated with an increase in local
reactions(24,28,30). Including only grade A and B studies in a
sensitivity analysis demonstrated a small non-significant
increased risk of local reactions associated with immunotherapy
(RR 2·08, 95 % CI 0·87, 4·99; see Appendix 5, Supplementary Fig.
S10, available online)(24,27,32,38). Subgroup analysis of data
obtained from trials on OIT for cows’ milk allergy suggested an
increased risk in the treatment arm, but this was imprecisely
estimated (RR 2·03, 95 % CI 0·87, 4·73; see Appendix 5, Sup-
plementary Fig. S11, available online).
Other outcomes. None of the studies had reported on the
other outcomes of interest, namely quality of life of patients
and their families; use of health services including emergency
hospital admissions and emergency treatments; and data on
cost-effectiveness considerations.
Details of unpublished and ongoing studies are summarised
in Appendix 8 (available online).
Discussion
Statement of principal findings
The present systematic review and meta-analysis has found
that orally administered immunotherapy is likely to be effec-
tive in substantially reducing the risk of persisting food allergy
in children and adults with IgE-mediated food allergy to a
range of foods while receiving treatment (i.e. desensitisation
was successfully achieved). The increases in allergen exposure
that people are able to tolerate while on treatment are clini-
cally relevant and are likely to prevent many of the reactions
associated with accidental exposure. It remains unclear as to
whether orally administered immunotherapy induces clinical
tolerance (i.e. long-term cure). For example, Burks et al.(24)
reported that OIT induced tolerance in 28 % of those treated,
whereas Staden et al.(14) found no increase in tolerance over
and above that observed in the control subjects. The lack of
consensus on clinical tolerance is important because of the
need for regular exposure to allergenic foods to maintain a
state of desensitisation. These treated patients, therefore, at
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Fig. 7. Specific IgE levels (kU/l) following oral immunotherapy for food allergy. (A colour version of this figure can be found online at http://www.journals.
cambridge.org/bjn)
Study or subgroup
Pajno 2010(35)
Skripak 2008(18)
Varshney 2011(38)
Total (95 % CI)
Heterogeneity: t2 = 0·00; c2 = 1·87, df = 2 (P = 0·39); I 2 = 0 %
Test for overall effect: Z = 14·27 (P < 0·00001)
Mean
4·37
6·3
0·48
SD
1·7
7·6
0·42
Total
15
7
9
31
Mean
23·8
45·9
25·49
SD
5·3
70·7
25·25
Total
15
13
19
47
Weight
(%)
93·7
0·5
5·8
100·0
–19·43
–39·60
–25·01
–19·85
95 % CI
–22·25, –16·61
–78·44, –0·76
–36·37, –13·65
–22·58, –17·12
Control Experimental Mean
difference
–100 –50 0 50 100
Favours controlFavours experimental
Mean difference
IV, Random, 95 % CI
Fig. 8. IgG4 levels (mg/ml) following oral immunotherapy for food allergy. (A colour version of this figure can be found online at http://www.journals.cambridge.org/bjn)
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present need to move from a situation in which they are meti-
culously avoiding the food in question to a state in which
regular consumption of the food is necessary in order to main-
tain a desensitised state. Such a state of desensitisation may be
associated with improved quality of life; however, the psycho-
logical consequences (if any) of such a radical change in
management strategy may in some individuals adversely
affect the quality of life. These issues need to be addressed
by appropriate trials. Immunotherapy is associated with an
increased risk of local side effects and, more importantly,
may also be associated with a modest increased risk of
systemic side effects, necessitating very careful intensive
monitoring of patients and high-level clinical support (i.e.
access to specialist advice 24h a day, 7 d a week). The cost
implications for health services of treating immunotherapy-
associated adverse events, the supervision of immunotherapy
dose increases in clinical areas and the provision of high-level
clinical support have not been addressed by any of the studies
identified and also clearly need further investigation.
Insights into the mechanisms of action
In contrast to previous reviews on this subject(20,43–49), we
also studied and synthesised data on immunological
outcomes. Overall, the immunological data suggest that
orally administered immunotherapy induces changes in skin
prick tests (reduced response) and antigen-specific IgG4
levels (increased) similar to those reported with conventional
allergen immunotherapy and during the natural early-life
development of tolerance to food allergens(50). The majority
of the studies reported that orally administered immunother-
apy did not reduce allergen-specific IgE levels, and this was
confirmed by the meta-analysis. The disparity in the ability
of orally administered immunotherapy to reduce skin prick
test reactivity to the responsible allergens while failing to
reduce serum allergen-specific IgE levels may be a conse-
quence of increased levels of allergen-specific IgG4 inhibiting
IgE cross-linking by competing with IgE for the binding of
allergens(51). It is also possible that reduced skin prick test
reactivity may be a consequence of the effects of orally admi-
nistered immunotherapy on non-IgE components of the skin
prick test, e.g. mast cells, or possibly the generation of IgE
with a reduced binding affinity for the allergens.
Strengths and weaknesses of this work
We believe that this is the most comprehensive and detailed
systematic review and meta-analysis on this subject ever
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Fig. 9. Safety data – absence of systemic reactions during oral immunotherapy or sublingual immunotherapy for food allergy. RR, risk ratio. (A colour version of
this figure can be found online at http://www.journals.cambridge.org/bjn)
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Fig. 10. Safety data – absence of local reactions during oral immunotherapy or sublingual immunotherapy for food allergy. RR, risk ratio. (A colour version of this
figure can be found online at http://www.journals.cambridge.org/bjn)
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undertaken. This work has been conducted to international
standards and, furthermore, has both drawn on a substantially
greater evidence base and has considerable methodological
strengths over previous reviews on this subject(20,43–49). It pro-
vides a state-of-the-art overview of the experimental evidence
on this clinically important subject together with detailed sub-
group/sensitivity analyses based on allergy to specific foods,
mode of immunotherapy and study design. The quality assess-
ment acknowledged the inherent weakness of uncontrolled
trials in young children with food allergy, whereby food
allergies in early life naturally resolve as tolerance develops,
e.g. cows’ milk allergy.
The main potential limitations of this work stem from the
heterogeneity of the populations, interventions and outcomes
studied/reported on; it is, therefore, important that, in
keeping with the random-effects meta-analyses employed,
care be taken in interpreting the findings as average effects
across studies. That said, our various subgroup and
sensitivity analyses, with accompanying reductions in hetero-
geneity in some cases (see Fig. 2(b) and (c), Appendix 5,
Figs. S1 and S4, available online), generated broadly compar-
able findings, which suggests that the overall conclusions are
very likely to be robust. Although we found that orally
administered immunotherapy is associated with an increased
likelihood of relatively mild local side effects, because of
inconsistencies in the definition and reporting, our meta-
analyses of side effects were limited to a minority of studies
and to a handful of studies at a low risk of bias. Clearly,
further trials using standardised reporting of side effects are
required to fully assess the risks associated with orally admi-
nistered immunotherapy. A further limitation is the failure of
some investigators to provide us with original data; however,
the reported effects of immunotherapy in these studies
are consistent with the results of our meta-analyses. Future
studies also need to determine longer-term outcomes, as
most studies to date have been short-term ones with less
than 2 years of follow-up. Finally, we have uncovered data
on ongoing studies, the findings of which will, once incorpor-
ated into our planned updates of this systematic review and
meta-analysis, offer greater precision around the summary
estimates.
Implications for clinical care and further research
In summary, orally administered immunotherapy for
IgE-mediated food allergy is a promising re-emerging treat-
ment approach, which has the potential to play an important
disease-modifying role in people with a range of food aller-
gies. Current treatment regimens are, however, associated
with an increased risk of local reactions and possibly also
more serious systemic reactions; therefore, orally administered
immunotherapy is not suitable for use in routine clinical care
and should not under any circumstances be considered as a
self-administered treatment approach. There is a pressing
need to develop safer treatment protocols and establish the
longer-term effectiveness, safety and cost-effectiveness of
this potentially curative treatment approach.
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